小肿瘤型HER2阳性乳腺癌的免疫特征:APT试验的二次分析
APT试验是一项多中心、单臂、II期研究,纳入406例淋巴结阴性、肿瘤≤3 cm的HER2阳性乳腺癌患者,接受紫杉醇联合曲妥珠单抗治疗。本二次分析对328例患者进行肿瘤浸润淋巴细胞、PD-L1表达及免疫基因特征检测,发现小肿瘤型HER2阳性乳腺癌的免疫特征因激素受体状态、组织学分级和分子亚型而异。
要点
- 高TIL(≥60%)更常见于激素受体阴性、组织学2-3级及HER2富集型和基底样肿瘤。
- 低间质PD-L1(≤1%)更常见于激素受体阳性、组织学1级及管腔型肿瘤。
- TIL和间质PD-L1均与10种免疫细胞特征正相关,管腔B型肿瘤与这些特征负相关。
核心结论
- 小肿瘤型HER2阳性乳腺癌的免疫特征因激素受体状态、组织学分级和分子亚型而异。
- 需要进一步研究以探索这些发现对疾病结局的影响。
研究设计与样本
- APT试验是一项多中心、单臂、II期研究,评估紫杉醇联合曲妥珠单抗用于淋巴结阴性HER2阳性乳腺癌。
- 研究纳入406例HER2阳性、淋巴结阴性、肿瘤≤3 cm的乳腺癌患者。
- 本二次分析对328例(81%)患者进行了至少一项免疫检测:284例评估TIL,266例评估PD-L1,213例评估免疫基因特征。
主要发现
- 高TIL(≥60%)更常见于激素受体阴性、组织学2级和3级以及HER2富集型和基底样肿瘤。
- 低间质PD-L1(≤1%)表达更常见于激素受体阳性、组织学1级和管腔型肿瘤。
- TIL和间质PD-L1均与10种免疫细胞特征正相关,包括Th1和B细胞特征。
- 管腔B型肿瘤与这些免疫特征负相关。
- 这些免疫标志物之间存在显著相关性,但相关程度并未表明它们之间呈单调关系。
关键数值与推荐
- 高TIL定义为≥60%。
- 低间质PD-L1定义为≤1%。
- 免疫基因特征使用nCounter PanCancer Pathways Panel(NanoString Technologies,西雅图,华盛顿州)数据。
- PD-L1表达通过免疫组织化学检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以探索这些发现对疾病结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics. PATIENTS AND METHODS: The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, node-negative breast cancer, measuring up to 3 cm. Exploratory analysis of tumor infiltrating lymphocytes (TIL), programmed death-ligand 1 (PD-L1) expression (by immunohistochemistry), and immune gene signatures using data generated by nCounter PanCancer Pathways Panel (NanoString Technologies, Seattle, WA), and their association with pathological and molecular characteristics was carried out. RESULTS: Of the 406 patients, 328 (81%) had at least one immune assay carried out: 284 cases were evaluated for TIL, 266 for PD-L1, and 213 for immune gene signatures. High TIL (≥60%) were seen with greater frequency in hormone-receptor (HR) negative, histological grades 2 and 3, as well in HER2-enriched and basal-like tumors. Lower stromal PD-L1 (≤1%) expression was seen with greater frequency in HR-positive, histological grade 1, and in luminal tumors. Both TIL and stromal PD-L1 were positively correlated with 10 immune cell signatures, including Th1 and B cell signatures. Luminal B tumors were negatively correlated with those signatures. Significant correlation was seen among these immune markers; however, the magnitude of correlation did not indicate a monotonic relationship between them. CONCLUSION: Immune profiles of small HER2-positive breast cancers differ according to HR status, histological grade, and molecular subtype. Further work is needed to explore the implication of these findings on disease outcome. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00542451.
引用
- Barroso-Sousa R, Barry WT, Guo H, et al. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019. PMID: 30753274. doi:10.1093/annonc/mdz047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。